Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
暂无分享,去创建一个
Z. Szallasi | G. Mills | E. Winer | A. Richardson | W. Barry | K. Jensen | A. Gutin | J. Reid | J. Garber | N. Tung | V. Abkevich | B. Hennessy | D. Silver | D. Iliev | J. Lanchbury | S. Isakoff | A. Greene-Colozzi | A. Hartman | K. Timms | P. Ryan | M. Telli | C. Neff | Z. Sangale | J. Ford | Joshua T. Jones | Zaina Sangale | April Greene-Colozzi
[1] K. Jensen,et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer , 2018, Breast Cancer Research and Treatment.
[2] M. Rezai,et al. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. , 2015 .
[3] Nicolai J. Birkbak,et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs , 2015, Biomarker Research.
[4] James M Ford,et al. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Berry,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Pruss,et al. A comprehensive laboratory‐based program for classification of variants of uncertain significance in hereditary cancer genes , 2014, Clinical genetics.
[7] M. Rezai,et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[8] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[9] D. Berry,et al. Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL , 2013 .
[10] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[11] A. Vincent-Salomon,et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.
[12] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[13] D. Livingston,et al. Mechanisms of BRCA1 tumor suppression. , 2012, Cancer discovery.
[14] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[15] J. Schiffman,et al. Molecular inversion probes: a novel microarray technology and its application in cancer research. , 2012, Cancer genetics.
[16] Z. Szallasi,et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.
[17] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[18] E. Alli,et al. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. , 2010, Cancer research.
[19] C. Perou,et al. Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.
[20] G. Mills,et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Z. Szallasi,et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Winer,et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] E. Alli,et al. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. , 2009, Cancer research.
[24] J. Kładny,et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2009, Breast Cancer Research and Treatment.
[25] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Ashworth,et al. BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.
[27] Shridar Ganesan,et al. X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.
[28] Julian Peto,et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.
[29] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[30] Sridhar Ramaswamy,et al. Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers , 2004, Cancer Research.
[31] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.